News
-
The Australian Research Council (ARC) has awarded a 3-year, $482,738 linkage grant titled “One for all and all for one- Engineering a drug delivery platform for DNA vaccines to the lung” to members of the… Read more . . .
-
The US FDA has announced the approval of MannKind Corporation’s Afrezza inhaled insulin for the treatment of diabetes. The PDUFA date for Afrezza had been set for July 15, 2014 after the FDA’s Endocrinologic and… Read more . . .
-
Overall Responsibility: We are seeking a highly motivated, experienced senior scientist or engineer to join the Pharmaceutical Development group to provide technical leadership and hands-on performance in support of Pulmatrix development programs. This position will… Read more . . .
-
Powder characterization specialist Freeman Technology is offering a free 35-page downloadable booklet titled “An Introduction to Powders” that includes information particularly useful for development and optimization of dry powder inhalers, the company says. Authored by… Read more . . .
-
The US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended that children aged 2-8 should get a nasal spray flu vaccine if available instead of an injection. The… Read more . . .
-
Device component company Presspart Manufacturing has announced that former Lupin pulmonary research scientist Abhay Singh and former Sanofi QC readiness analyst Jacqueline Green have joined Presspart’s Inhalation Product Technology Centre (IPTC) team. Singh has been… Read more . . .
-
According to Aradigm, the first patient in the Phase 3 ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial of Pulmaquin inhaled ciprofloxacin for the treatment of non-cystic fibrosis bronchiectasis has been dosed. The other Phase 3… Read more . . .
-
Verona Pharma has announced that it will stop development of its VRP700 inhaled antitussive after the drug failed to produce statistically significant reduction in cough frequency compared to placebo in a Phase 2a clinical trial.… Read more . . .
-
Under the terms of a newly reached settlement, Perrigo and Catalent will be able to market limited quantities of their generic version of Teva’s Proair HFA albuterol MDI starting in December 2016. Beginning in July… Read more . . .
-
Asmacure has announced that a Phase 1/2a trial of ASM-024 inhalation powder found that the drug was safe and well tolerated. In April 2013, the company announced that it had dosed the first patient in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.